Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...
Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...
An experimental pill from Boston-based Rapport Therapeutics narrowly succeeded in a mid-stage study focused on bipolar mania, an outcome that analysts described as unexpected and a potential stepping ...
Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a ...
Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a ...
Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...
Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...
The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi ...
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...
Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results